Géraudie Amandine, De Rossi Pierre, Canney Michael, Carpentier Alexandre, Delatour Benoît
Paris Brain Institute, ICM, Inserm U1127, CNRS UMR 7225, Sorbonne University, 75013 Paris, France.
Carthera, 1 Pl. Vaclav Havel, 69007 Lyon, France.
J Control Release. 2025 Mar 10;379:1029-1044. doi: 10.1016/j.jconrel.2025.01.056. Epub 2025 Feb 4.
Blood-brain barrier opening with ultrasound can potentiate drug efficacy in the treatment of brain pathologies and also provides therapeutic effects on its own. It is an innovative tool to transiently, repeatedly and safely open the barrier, with studies showing beneficial effects in both preclinical models for Alzheimer's disease and recent clinical studies. The first preclinical and clinical work has mainly shown a decrease in amyloid burden in mice models and in patients. However, Alzheimer's disease pathology also encompasses tauopathy, which is closely related to cognitive decline, making it a crucial therapeutic target. The effects of blood-brain barrier opening with ultrasound have been rarely assessed on tau and are still unclear.
This systematic review, conducted through searches using Pubmed, Embase, Web of Science and Cochrane Central databases, extracted results of 15 studies reporting effects of blood-brain barrier opening using ultrasound on tau proteins.
This review of the literature indicates that blood-brain barrier opening using ultrasound can decrease the extent of the tau pathology or potentialize the effect of a therapeutic drug. However, selected studies report paradoxically that blood-brain barrier opening can increase tau pathology burden and induce brain damage.
Apparent discrepancies between reports could originate from the variability in protocols or analytical methods that may impact the effects of blood-brain barrier opening with ultrasound on tauopathies, glial populations, tissue integrity and functional outcomes.
This calls for a better standardization effort combined with improved methodologies allowing between-studies comparisons, and for further understanding of the effects of blood-brain barrier opening on tau pathology as an essential prerequisite before translation to clinic.
利用超声打开血脑屏障可增强药物在治疗脑部疾病中的疗效,并且其自身也具有治疗作用。它是一种用于短暂、反复且安全地打开血脑屏障的创新工具,多项研究表明其在阿尔茨海默病的临床前模型和近期的临床研究中均具有有益效果。首批临床前和临床研究主要显示了小鼠模型和患者脑中淀粉样蛋白负荷的降低。然而,阿尔茨海默病的病理变化还包括与认知衰退密切相关的tau蛋白病变,这使其成为一个关键的治疗靶点。超声打开血脑屏障对tau蛋白的影响很少被评估,目前仍不清楚。
通过检索PubMed、Embase、Web of Science和Cochrane Central数据库进行了这项系统评价,提取了15项报告超声打开血脑屏障对tau蛋白影响的研究结果。
该文献综述表明,利用超声打开血脑屏障可降低tau蛋白病变的程度或增强治疗药物的效果。然而,部分研究却反常地报告称,打开血脑屏障会增加tau蛋白病变负担并导致脑损伤。
报告之间明显的差异可能源于方案或分析方法的变异性,这可能会影响超声打开血脑屏障对tau蛋白病变、神经胶质细胞群体、组织完整性和功能结果的影响。
这需要更好地进行标准化工作并改进方法以实现研究间的比较,并且在转化应用于临床之前,需要进一步了解打开血脑屏障对tau蛋白病变的影响,这是至关重要的前提条件。